Evidence map›Paper›PMID 28598901›Full record

ReviewCurrent opinion in pediatrics2017

HIV preexposure prophylaxis for adolescents and young adults.

Emily Allen, Allegra Gordon, Douglas Krakower, Katherine Hsu

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Experiences of Successful PrEP Uptake Among Adolescent Sexual Minority Men in the United States: A Qualitative Exploration.AIDS education and prevention : official publication of the International Society for AIDS Education · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Emily AllenaDivision of Adolescent/Young Adult Medicine, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School bFenway Health, The Fenway Institute cDivision of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School dDivision of STD Prevention and HIV/AIDS Surveillance, Massachusetts Department of Public Health, Jamaica Plain eSection of Pediatric Infectious Diseases, Department of Pediatrics, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA.
Allegra Gordon
Douglas Krakower
Katherine Hsu
Boston Children's Hospital · USBoston Medical Center · USFenway Health · USHarvard University · US

Funding

Optimizing HIV Pre-Exposure Prophylaxis through Shared Decision MakingK23MH098795 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KRAKOWER, DOUGLAS SCOTT · 2012 to 2016
$873k
Changes in the Social and Policy Environment as Predictors of Substance Use and Health-Related Quality of Life Among Sexual MinoritiesF32DA042506 · NIDA · BOSTON CHILDREN'S HOSPITAL · PI GORDON, ALLEGRA RABOFF · 2016 to 2018
$188k
NIDA NIH HHS F32 DA042506NIMH NIH HHS K23 MH098795
6 · The paper itself

Abstract

purpose of reviewThe review describes the evidence for HIV preexposure prophylaxis (PrEP) with daily combined tenofovir disoproxil fumarate and emtricitabine for adolescents and young adults. Current recommendations are described, as are the unique medical, socioeconomic, and legal considerations regarding the use of PrEP for youth. RECENT

findingsPrEP with daily oral tenofovir disoproxil fumarate-emtricitabine has been shown to help prevent new HIV infection among adults at substantial risk. Evidence suggests a protective benefit of PrEP for youth at risk for HIV, although low adherence is emerging as a barrier to effective use. SUMMARY: Effective use of antiretrovirals for PrEP represents a seminal development in HIV prevention efforts. Improving access and adherence to PrEP for youth has the potential to substantially reduce the incidence of HIV in this population.

Indexed as

AdolescentAnti-HIV AgentsEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHIV InfectionsHumansPre-Exposure ProphylaxisTreatment OutcomeYoung AdultAnti-HIV AgentsEmtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

Identifiers

PMID28598901
PMCPMC5762125
OpenAlexW2622107498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.